B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases

被引:61
|
作者
Perry, Anamarija M. [1 ]
Crockett, David [2 ]
Dave, Bhavana J. [3 ]
Althof, Pamela [3 ]
Winkler, Lisa [3 ]
Smith, Lynette M. [4 ]
Aoun, Patricia [5 ]
Chan, Wing C. [6 ]
Fu, Kai [6 ]
Greiner, Timothy C. [6 ]
Bierman, Phillip [2 ]
Bociek, Robert Gregory [2 ]
Vose, Julie M. [2 ]
Armitage, James O. [2 ]
Weisenburger, Dennis D. [5 ]
机构
[1] Univ Manitoba, Dept Pathol, Winnipeg, MB R3T 2N2, Canada
[2] Univ Nebraska Med Ctr, Dept Internal Med, Duarte, CA USA
[3] Univ Nebraska Med Ctr, Human Genet Lab, Munroe Meyer Inst, Duarte, CA USA
[4] Univ Nebraska Med Ctr, Dept Biostat, Duarte, CA USA
[5] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA
[6] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
关键词
diffuse large B-cell lymphoma; Burkitt lymphoma; unclassifiable B-cell lymphoma; MYC; BCL2; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; MYC REARRANGEMENT; BCL2; VINCRISTINE; DOXORUBICIN; DISTINCT;
D O I
10.1111/bjh.12343
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
B-cell lymphoma, unclassifiable (B-UCL), with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B-UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for years 1985-2010 for cases of B-UCL. Immunohistochemical stains and fluorescence in situ hybridization studies for MYC, BCL2 and BCL6 gene rearrangements were performed. Among the 39 cases studied, 54% were male and 46% were female, with a median age of 69years. The majority of patients presented with advanced-stage disease (62%) and had high (3-5) International Prognostic Index (IPI) scores (54%). The median overall survival (OS) was only 9months and the 5-year OS was 30%. Patients with low IPI scores (0-2) had a better survival than those with high scores (3-5). The cases were genetically heterogeneous and included 11 double-hit' lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features was predictive of survival. This B-cell lymphoma is a morphologically-recognizable entity with a spectrum of genetic abnormalities. New and better treatments are needed for this aggressive lymphoma.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 50 条
  • [41] Diffuse large B-cell lymphoma in the older
    Gutierrez, A.
    Mestre, F.
    Perez-Manga, G.
    Rodriguez, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (01) : 59 - 72
  • [42] Pancreatic Diffuse Large B-cell Lymphoma in the
    Ullah, Asad
    Lee, Kue T.
    Malham, Kali
    Yasinzai, Abdul Qahar Khan
    Tareen, Bisma
    Lopes, Dara
    Wali, Agha
    Zarate, Luis Velasquez
    Waheed, Abdul
    Wiest, Maya
    Hakim, Resham
    Khan, Marjan
    Asif, Bina
    Patel, Nikhil
    Hakim, Sahar
    Kakar, Kaleemullah
    Heneidi, Saleh
    Karki, Nabin R.
    Sidhwa, Feroze
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [43] Genetics of Diffuse Large B-Cell Lymphoma
    Naresh, Kikkeri N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05): : 493 - 493
  • [44] The management of diffuse large B-cell lymphoma
    Liapis, K.
    Karmiris, T.
    ARCHIVES OF HELLENIC MEDICINE, 2010, 27 (01): : 48 - 65
  • [45] Diffuse large B-cell lymphoma in elderly
    Wrobel, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2012, 8 (01): : 36 - 40
  • [46] MicroRNAs in diffuse large B-cell lymphoma
    Ni, Huiyun
    Tong, Rong
    Zou, Linqing
    Song, Guoqi
    Cho, William C.
    ONCOLOGY LETTERS, 2016, 11 (02) : 1271 - 1280
  • [47] Treatment of Diffuse Large B-Cell Lymphoma
    Miyazaki, Kana
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2016, 56 (02) : 79 - 88
  • [48] Diffuse large B-cell lymphoma physiopathology
    Molina, Thierry Jo
    HEMATOLOGIE, 2009, 15 (03): : 214 - 222
  • [49] Cost burden of diffuse large B-cell lymphoma
    Harkins, R. Andrew
    Patel, Sharvil P.
    Flowers, Christopher R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (06) : 645 - 661
  • [50] Emerging drugs for diffuse large B-cell lymphoma
    Mondello, Patrizia
    Younes, Anas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (04) : 439 - 451